Audit: QRS - Convolvulus pluricaulis for Health & Longevity

Audit conducted on 17/08/2026 18:36 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	85
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Spot-checked every populated span: protocol doses (ER 332-334, 340, 344), time-to-effect (ER 386, 161), benefit and risk tiers (ER 149-203, 227-267), gates (ER 283-310), all nine monitoring rows and cadence (ER 408-420), qualitative markers (ER 424-429).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	marker_9_target carries “No established target; the change from the individual’s own baseline is what is tracked” verbatim from ER line 420; “highest verified human dose” and “only validated condition” retained.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindication strength preserved: phenytoin and pregnancy remain absolute stop items; TSH >4.0 mIU/L threshold retained; “(caution)” / “(monitor)” markers on interactions carried through unchanged.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from the ER’s “Populations who should avoid” list; Key Interactions only from the ER interaction bullets; no Benefit- or Risk-Modifying Factor content appears in any gate or tier.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, no author names, no NCT identifiers and no brand names anywhere in the QRS; only generic drug names that the ER itself lists.
1.6	The QRS does not introduce new attributions.	🟢	No institution, author or platform is named; references are generic (“both human cognitive studies”, “the animal study”) and match the ER.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Same declarative, evidence-first register; British spellings of the ER retained (“Favourable”, “anaesthesia”).
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Numeric targets, doses and windows throughout; the At-A-Glance names the one actionable lever (verified identity and metal testing) without alarmism.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Statements describe what studies did and what is measured, e.g. “Split, twice daily after food is the only validated condition” rather than an instruction.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives and no second person anywhere in the document body; the only normative text is the fixed template disclaimer in the footer.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrence of “recommend”, “advise”, “should” or “must” in any content span.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	Grep for you/your/we/our/us returns no match.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms used are the ER’s own headings and biomarker names (“psychomotor slowing”, “glycemic control”, “Free T3”); no jargon is introduced beyond the ER.
2.8	Information is presented in a concise and very compact manner	🟢	Gate and tier items are stripped to key facts; protocol subs are one to two short sentences.
2.9	It DOES NOT address the reader directly	🟢	No direct address; confirmed by the same grep as 2.6.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Content assumes willingness to run a fasting panel, a twice-weekly blood-pressure log and an 8-week evaluation window.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Nine-marker monitoring panel including whole-blood lead and plasma phenytoin is retained rather than trimmed for convenience.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Optimal functional ranges (e.g. TSH 0.5-2.0 mIU/L, lead below 1.0 µg/dL) are tighter than conventional reference ranges, which addresses the optimizing reader.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-A-Glance states plainly that nothing is placebo-tested and that sourcing beats dose refinement — the weighting that matters to a self-directed user.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not occur; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“tablets”, “powder”, “anaesthesia”, “hypotension”, “thyroid-stimulating hormone” — all formal and all matching the ER’s own register.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	Verified at lines 446, 492, 541, 628, 654, 803 (headings), 569 and 582 (gates), 544/547/551/557 and 631/635/641/645 (tiers), 658-660 (table headers).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	67 uniquely named spans present, each exactly once: page_title, header_topic, header_subline_date, header_subline_model, at_a_glance, action_1-3 label/value/sub, time_1-3 label/value/sub, benefits and risks tiers, stop_items, caution_items, marker_1-9 name/target/why, monitoring_cadence, qualitative_item_1-6.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The non-variable template spans website="evidence_review", website="audit" and website="full_review" (lines 423, 426, 440) are untouched; hidden tier spans retain their original placeholder <li><strong>High: </strong></li> markup.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No QRS section maps to an empty ER section; the unpopulated benefit and risk tiers are governed by items 12.5 and 13.5, which require display: none rather than empty-state phrasing.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels (“Whole-powder course (traditional Ayurvedic approach)”, “Processed-tablet course”, “Best time of day”) and all nine interaction labels reproduce the ER bold labels including their “(caution)” / “(monitor)” markers.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Monitoring marker names and biomarker targets match the ER table cells exactly; qualitative items match ER lines 424-429 verbatim; the time-to-effect labels are the only derived labels, and the ER supplies no per-aspect bold label there.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji characters in the file; tiers are conveyed by the .benefits / .risks CSS palettes and bold tier labels.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Per-section budgets respected: gate items reduced to bare facts, benefit and risk tiers collapsed into single semicolon-separated lines, monitoring “Context/Notes” column dropped entirely, protocol subs held to two short sentences.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2-14; it is the first element after the doctype and precedes the template comment at line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the preamble text “QRS — Metadata (invisible, parsed by audit tooling)” sits before the opener.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Contained wholly in an HTML comment; no metadata value is repeated in head or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:05" is quoted, correctly so because it contains a colon; all other values are bare and untrimmed of nothing.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: convolvulus_pluricaulis_2026-0825-1523_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0817-1817, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version only, no context-window or tier qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file on disk: convolvulus_pluricaulis_2026-0825-1523_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; consistent with 5.4.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Convolvulus pluricaulis for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Convolvulus pluricaulis for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 08/17/2026, correctly derived from qrs_creation_date: 2026-0817-1817.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only title and the template subline; the ER’s “Also known as” line and its eight synonyms are absent, as are any badge or audit stamp.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Four clauses drawn from ER lines 453-455, closing on the actionable point that verified identity and metal testing outrank dose refinement.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	“inexpensive Indian herb … two thousand years” and “broad in animals and thin in people” (ER 453); “Nothing has been tested against a placebo” (ER 453, verbatim); phenytoin as the only human-evidenced harm (ER 455); sourcing over dose (ER 455).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “phenytoin” is glossed in place as “the anti-seizure drug”; remaining vocabulary (memory, calm, placebo, metal testing) is everyday.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No author, year, sample size or p-value; only the unnamed generic “Young adults reported better delayed recall”.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	The ER’s 48% / 44.9% delayed-recall figures (ER 155) are deliberately omitted.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All six items map one-to-one onto the ER’s “Populations who should avoid Convolvulus pluricaulis” list at ER lines 305-310.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Complete set: phenytoin/uncontrolled epilepsy, pregnancy and lactation, symptomatic hypotension, under-replaced hypothyroidism, imminent surgery, under-16s. Nothing added, nothing dropped.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Six <li> elements inside the stop_items span (lines 572-577).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	ER trailing rationales correctly stripped: “on grounds of complete absence of reproductive data” (ER 306) and “the lower bound of every human study of the single herb” (ER 310) are both gone; no dash-trailing clause remains.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Preserved: “not stably controlled for 12 months”, “at any dose”, “seated systolic blood pressure below 100 mmHg”, “(thyroid-stimulating hormone above 4.0 mIU/L)”, “within 14 days”, “under 16”.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s contraindication list uses no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names six such populations, and the section is correspondingly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items map to ER interaction bullets at lines 285-301, in the ER’s own order.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	The ER’s first bullet, “Phenytoin (absolute contraindication)” (ER 283), is correctly excluded here and carried in stop_items instead; the remaining nine bullets all appear.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Nine <li> elements inside the caution_items span (lines 585-618).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Mechanism and mitigation text stripped throughout, e.g. the ER’s “both blunt a blood-pressure hormone … Mitigations are staggered dosing and home blood-pressure logs” (ER 287) reduces to the label plus four drug names; no dash-trailing clause remains.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every drug-class exemplar list is retained in trimmed form (e.g. “benzodiazepines (diazepam), Z-drugs (zolpidem), opioids (oxycodone), alcohol”); no exemplar list is dropped entirely.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction bullets use no ranking notation inside parentheses.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names ten interactions, and the section is populated with the nine non-contraindicated ones.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells trace to the ER Therapeutic Protocol bullets at lines 332, 334, 340 and 344.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The two dose-bearing courses with established human exposure (whole powder, processed tablet) plus timing; the standardised-extract bullet is correctly passed over because the ER states “No human dose has been established” (ER 336).
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies more than three actionable aspects, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	Values “3-6 g twice daily”, “500 mg twice daily” and “Evening or morning” each carry an ER-sourced sub line; no placeholder text remains.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Memory at 45-60 days (ER 386), menopause symptom and anxiety burden at 45 days (ER 161), sedation within hours (ER 386) — the only three windows the ER reports.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Order follows the ER’s own tiering: the two Low-tier benefits first, in the ER’s sequence, then the Speculative sedation effect.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects, so all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	Values “45-60 days”, “45 days”, “Within hours” each carry an ER-sourced sub line; time_2_sub mirrors the ER magnitude statement at line 161.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (ER 386), so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Both Low-tier and all ten Speculative-tier headings from ER lines 151-203 are represented.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 543, 546, 549 and 555.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a bare semicolon-separated list of ER benefit headings; the ER’s magnitude figures, “⚠️ Conflicted” markers and study descriptions are all omitted.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in either populated tier; the ER’s parenthetical glosses such as “(high blood sugar)” (ER 187) are absent.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER reports no High and no Medium benefit, and both spans carry style="display: none" with their untouched placeholder markup (lines 543-548).

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All three Medium, the single Low and all three Speculative risk headings from ER lines 229-267 are represented.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 630, 633, 640 and 643.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Bare heading lists only; the ER’s magnitude paragraphs (20.7% of 193 products, confidence interval, stigmasterol 31.9-155.0 mg/g) are all omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any populated tier; the ER’s “(the deliberate combining of herbs with metals and minerals)” and “(low blood sugar)” glosses are absent.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER reports no High risk, and risks_high carries style="display: none" with its untouched placeholder markup (lines 630-632).

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	All rows and the cadence trace to the ER Monitoring Protocol & Defining Success section (ER 408-420).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER table rows present in ER order — seated blood pressure, TSH, Free T3, fasting glucose, LDL cholesterol, ALT, whole-blood lead, plasma phenytoin, delayed-recall test score — with names, targets and rationales matching the ER cells.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 792-797 reproduce the ER’s baseline panel and front-loaded cadence, through to “every 6-12 months for as long as use continues”.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Drawn from the ER’s “Qualitative markers worth tracking alongside the labs” list (ER 424-429).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER items present verbatim and in ER order: sleep latency and depth, morning alertness and grogginess, subjective calm under load, recall of names and lists, steadiness on standing, coordination in skill-dependent training.

Issues 17/08/2026 18:36

Pass rate 100.00%. No issues found.

Issues 17/08/2026 18:28

1. 9.5 — Parenthetical drug examples dropped: Three interaction items strip the ER’s parenthetical example drugs entirely instead of trimming them — QRS line 594 omits diazepam, alprazolam, zolpidem, zopiclone, oxycodone and tramadol (ER line 289); line 599 omits glipizide and glimepiride (ER line 293); line 602 omits diphenhydramine and doxylamine (ER line 295). Two named list members are also dropped: magnesium glycinate (ER line 297) and high-dose omega-3 (ER line 299).

Fixes 17/08/2026 18:28

1. 9.5 — Parenthetical drug examples restored: Added one trimmed example drug per class to the three interaction items that had dropped the ER’s parentheticals entirely — “benzodiazepines (diazepam), Z-drugs (zolpidem), opioids (oxycodone), alcohol”, “sulfonylureas (glipizide)” and “sedating antihistamines (diphenhydramine)”. Also restored the two dropped list members, magnesium glycinate and high-dose omega-3.